Vascular growth factors in neuropsychiatry

Cellular and Molecular Life Sciences

Volumn 70, Issue 10, 2013, Pages 1739-1752

  Newton, Samuel S ^a   Fournier, Neil M ^a   Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erythropoietin; Neurovascular; Trophic factor signaling; Vascular endothelial growth factors

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; STAT PROTEIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 2;

AMYGDALOID NUCLEUS; ANGIOGENESIS; ANTIDEPRESSANT ACTIVITY; ASTROCYTE; BIOMIMETICS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN ISCHEMIA; CHRONIC STRESS; COGNITION; CRYSTAL STRUCTURE; DEPRESSION; DRUG MEGADOSE; ENDOTHELIAL PROGENITOR CELL; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROPSYCHIATRY; NONHUMAN; PREFRONTAL CORTEX; REMISSION; REVIEW; SINGLE DRUG DOSE;

EID: 84876942810     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1281-9     Document Type: Review

References (145)

1. Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54(7):597-606
2. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, Duman RS (2003) Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 23(34):10841-10851
3. Musselman DL, Evans DL, Nemeroff CB (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55(7):580-592
4. Carney RM, Freedland KE (2003) Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 54(3):241-247
5. Plante GE (2005) Depression and cardiovascular disease:a reciprocal relationship. Metabolism 54(5 Suppl 1):45-48
6. Salaycik KJ, Kelly-Hayes M, Beiser A, Nguyen AH, Brady SM, Kase CS, Wolf PA (2007) Depressive symptoms and risk of stroke: the Framingham study. Stroke 38(1):16-21
7. Teper E, O'Brien JT (2008) Vascular factors and depression. Int J Geriatr Psychiatry 23(10):993-1000
8. Ghoge H, Sharma S, Sonawalla S, Parikh R (2003) Cerebrovascular diseases and depression. Curr Psychiatry Rep 5(3):231-238
9. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997) 'Vascular depression' hypothesis. Arch Gen Psychiatry 54(10):915-922
10. Vlassenko A, Sheline YI, Fischer K, Mintun MA (2004) Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci 16(3):360-363
11. Kohn Y, Freedman N, Lester H, Krausz Y, Chisin R, Lerer B, Bonne O (2007) 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. J Nucl Med 48(8):1273-1278
12. Czeh B, Abumaria N, Rygula R, Fuchs E (2010) Quantitative changes in hippocampal microvasculature of chronically stressed rats: no effect of fluoxetine treatment. Hippocampus 20(1):174-185
13. Neigh GN, Owens MJ, Taylor WR, Nemeroff CB (2010) Changes in the vascular area fraction of the hippocampus and amygdala are induced by prenatal dexamethasone and/or adult stress. J Cereb Blood Flow Metab 30(6):1100-1104
14. James JM, Gewolb C, Bautch VL (2009) Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube. Development 136(5):833-841. doi: 10.1242/dev.028845
15. Raab S, Beck H, Gaumann A, Yuce A, Gerber HP, Plate K, Hammes HP, Ferrara N, Breier G (2004) Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 91(3):595-605
16. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28(2):131-138
17. Sondell M, Sundler F, Kanje M (2000) Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 12(12):4243-4254 (pii ejn1326)
18. Khaibullina AA, Rosenstein JM, Krum JM (2004) Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res Dev Brain Res 148(1):59-68 (pii S0165380603003328)
19. Jin K, Mao XO, Greenberg DA (2006) Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 66(3):236-242. doi: 10.1002/neu.20215
20. Fournier NM, Lee B, Banasr M, Elsayed M, Duman RS (2012) Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology 63(4):642-652. doi: 10.1016/j.neuropharm.2012.04.033
21. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99(18):11946-11950
22. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, Liu X, Wu H, Carmichael ST (2006) A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 26(4):1269-1274
23. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, Lin CS, Nikodem VM, Hempstead B, Flanders KC, Costantini F, Noguchi CT (2002) Erythropoietin receptor signalling is required for normal brain development. Development 129(2):505-516
24. Ransome MI, Turnley AM (2007) Systemically delivered erythropoietin transiently enhances adult hippocampal neurogenesis. J Neurochem 102(6):1953-1965
25. Leconte C, Bihel E, Lepelletier FX, Bouet V, Saulnier R, Petit E, Boulouard M, Bernaudin M, Schumann-Bard P (2011) Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 60(2-3):354-364
26. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604-4613
27. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12(12):5447-5454
28. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98(7):4044-4049
29. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76(1):105-116
30. Digicaylioglu M, Lipton SA (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412(6847):641-647
31. Csete M, Rodriguez L, Wilcox M, Chadalavada S (2004) Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett 359(1-2):124-126
32. Puskovic V, Wolfe D, Wechuck J, Krisky D, Collins J, Glorioso JC, Fink DJ, Mata M (2006) HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther 14(5):710-715
33. Xue YQ, Ma BF, Zhao LR, Tatom JB, Li B, Jiang LX, Klein RL, Duan WM (2010) AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther 17(1):83-94
34. Nicoletti JN, Shah SK, McCloskey DP, Goodman JH, Elkady A, Atassi H, Hylton D, Rudge JS, Scharfman HE, Croll SD (2008) Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 151(1):232-241
35. Zhu XH, Yan HC, Zhang J, Qu HD, Qiu XS, Chen L, Li SJ, Cao X, Bean JC, Chen LH, Qin XH, Liu JH, Bai XC, Mei L, Gao TM (2010) Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adult rats. J Neurosci 30(38):12653-12663
36. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB (2002) Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22(15):6401-6407
37. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111(12):1843-1851
38. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106(7):829-838
39. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L (2008) TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci USA 105(16):6185-6190
40. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118(1):103-113
41. Moskowitz MA, Lo EH, Iadecola C (2010) The science of stroke: mechanisms in search of treatments. Neuron 67(2):181-198
42. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA (2012) Midlife vs late-life depressive symptoms and risk of dementia: differential effects for alzheimer disease and vascular dementia. Arch Gen Psychiatry 69(5):493-498
43. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92(9):3717-3720
44. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8(4):666-676
45. Marti HH, Bernaudin M, Petit E, Bauer C (2000) Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 15:225-229
46. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT (2007) Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 282(35):25875-25883
47. Shingo T, Sorokan ST, Shimazaki T, Weiss S (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21(24):9733-9743
48. Monacci WT, Merrill MJ, Oldfield EH (1993) Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 264(4 Pt 1):C995-C1002
49. Marti HH, Risau W (1998) Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 95(26):15809-15814
50. Breier G, Albrecht U, Sterrer S, Risau W (1992) Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114(2):521-532
51. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89(2):607-648. doi: 10.1152/physrev.00031.2008
52. Ogunshola OO, Stewart WB, Mihalcik V, Solli T, Madri JA, Ment LR (2000) Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. Brain Res Dev Brain Res 119(1):139-153
53. Hayashi T, Abe K, Suzuki H, Itoyama Y (1997) Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 28(10):2039-2044
54. Madri JA (2009) Modeling the neurovascular niche: implications for recovery from CNS injury. J Physiol Pharmacol 60(Suppl 4):95-104
55. Yang SZ, Zhang LM, Huang YL, Sun FY (2003) Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. Anat Rec A Discov Mol Cell Evol Biol 274(1):851-856. doi: 10.1002/ar.a.10103
56. Newton SS, Duman RS (2004) Regulation of neurogenesis and angiogenesis in depression. Curr Neurovasc Res 1(3):261-267
57. Louissaint A Jr, Rao S, Leventhal C, Goldman SA (2002) Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34(6):945-960
58. Islamov RR, Chintalgattu V, Pak ES, Katwa LC, Murashov AK (2004) Induction of VEGF and its Flt-1 receptor after sciatic nerve crush injury. Neuroreport 15(13):2117-2121 (pii: 00001756-200409150-00024)
59. Choi JS, Kim HY, Cha JH, Choi JY, Chun MH, Lee MY (2007) Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 in rat hippocampus after transient forebrain ischemia. J Neurotrauma 24(3):521-531. doi: 10.1089/neu.2006.0139
60. Jin K, Mao XO, Eshoo MW, Nagayama T, Minami M, Simon RP, Greenberg DA (2001) Microarray analysis of hippocampal gene expression in global cerebral ischemia. Ann Neurol 50(1):93-103
61. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64(2):326-333
62. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y (1996) Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239(2):494-500
63. Santhanam AV, Smith LA, Nath KA, Katusic ZS (2006) In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol 291(2):H781-H786
64. Sautina L, Sautin Y, Beem E, Zhou Z, Schuler A, Brennan J, Zharikov SI, Diao Y, Bungert J, Segal MS (2009) Induction of nitric oxide by erythropoietin is mediated by the beta common receptor and requires interaction with VEGF receptor 2. Blood 115(4):896-905
65. Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001(112):re21. doi: 10.1126/stke.2001.112.re21
66. Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F, Heumann R, Buhrer C, Ikonomidou C, Hansen HH (2004) Erythropoietin protects the developing brain against N-methyl-d-aspartate receptor antagonist neurotoxicity. Neurobiol Dis 15(2):177-187
67. Girgenti MJ, Hunsberger J, Duman CH, Sathyanesan M, Terwilliger R, Newton SS (2009) Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 66(3):267-274
68. Chavez JC, Baranova O, Lin J, Pichiule P (2006) The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26(37):9471-9481
69. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269(30):19488-19493
70. Schoch HJ, Fischer S, Marti HH (2002) Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125(Pt 11):2549-2557
71. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, Dirnagl U, Meisel A (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22(23):10291-10301
72. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H (2002) Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 44(4):391-403
73. Diaz Z, Assaraf MI, Miller WH Jr, Schipper HM (2005) Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem 93(2):392-402
74. Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, Cerami A, Andersson U, Zelenina M, Aperia A (2009) Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci USA 106(5):1602-1607
75. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP (2002) Arterial endothelial function is impaired in treated depression. Heart 88(5):521-523
76. Wagner JA, Tennen H, Mansoor GA, Abbott G (2006) History of major depressive disorder and endothelial function in postmenopausal women. Psychosom Med 68(1):80-86. doi: 10.1097/01.psy.0000195868.68122.9e
77. Jansson L, Hellsten J, Tingstrom A (2006) Region specific hypothalamic neuronal activation and endothelial cell proliferation in response to electroconvulsive seizures. Biol Psychiatry 60(8):874-881. doi: 10.1016/j.biopsych.2005.11.019
78. Smith PJ, Blumenthal JA, Babyak MA, Hoffman BM, Doraiswamy PM, Waugh R, Hinderliter A, Sherwood A (2007) Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. Psychosom Med 69(6):578-586. doi: 10.1097/PSY.0b013e31812f7b8e
79. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR Jr (2001) Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry 50(3):159-170 (pii: S0006322301011234)
80. Videbech P, Ravnkilde B, Pedersen AR, Egander A, Landbo B, Rasmussen NA, Andersen F, Stodkilde-Jorgensen H, Gjedde A, Rosenberg R (2001) The Danish PET/depression project: PET findings in patients with major depression. Psychol Med 31(7):1147-1158
81. Norbury R, Mannie Z, Cowen PJ (2011) Imaging vulnerability for depression. Mol Psychiatry 16(11):1067-1068. doi: 10.1038/mp.2011.44
82. Savitz JB, Drevets WC (2009) Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 164(1):300-330. doi: 10.1016/j.neuroscience.2009.03.082
83. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME (2007) Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 61(2):198-209. doi: 10.1016/j.biopsych.2006.05.048
84. Dome P, Halmai Z, Dobos J, Lazary J, Gonda X, Kenessey I, Sallai T, Makkos Z, Faludi G (2012) Investigation of circulating endothelial progenitor cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression. J Affect Disord 136(3):1159-1163. doi: 10.1016/j.jad.2011. 09.027
85. Dome P, Teleki Z, Rihmer Z, Peter L, Dobos J, Kenessey I, Tovari J, Timar J, Paku S, Kovacs G, Dome B (2009) Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol Psychiatry 14(5):523-531. doi: 10.1038/sj.mp.4002138
86. d'Audiffret AC, Frisbee SJ, Stapleton PA, Goodwill AG, Isingrini E, Frisbee JC (2010) Depressive behavior and vascular dysfunction: a link between clinical depression and vascular disease? J Appl Physiol 108(5):1041-1051. doi: 10.1152/japplphysiol.01440.2009
87. Giardina WJ, Ebert DM (1989) Positive effects of captopril in the behavioral despair swim test. Biol Psychiatry 25(6):697-702 (pii: 0006-3223(89)90240-0)
88. Gard PR, Mandy A, Sutcliffe MA (1999) Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 45(8):1030-1034 (pii: S0006-3223(98)00101-2)
89. Renshaw PF, Parsegian A, Yang CK, Novero A, Yoon SJ, Lyoo IK, Cohen BM, Carlezon WA Jr (2009) Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacol Biochem Behav 92(1):88-92. doi: 10.1016/j.pbb.2008.10.017
90. Srivastava SK, Nath C (2000) The differential effects of calcium channel blockers in the behavioural despair test in mice. Pharmacol Res 42(4):293-297. doi: 10.1006/phrs.2000.0696
91. 2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. Eur J Pharmacol 247(1):101-102
92. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T (2007) Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31(3):658-663. doi: 10.1016/j.pnpbp.2006.12.011
93. Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, Schweiger U (2009) Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34(3):353-357. doi: 10.1016/j.psyneuen.2008.09.016
94. Lee BH, Kim YK (2012) Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J Affect Disord 136(1-2):181-184. doi: 10.1016/j.jad.2011.07.021
95. Isung J, Mobarrez F, Nordstrom P, Asberg M, Jokinen J (2011) Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. doi: 10.3109/15622975.2011.624549
96. Fowles ER, Murphey C, Ruiz RJ (2011) Exploring relationships among psychosocial status, dietary quality, and measures of placental development during the first trimester in low-income women. Biol Res Nurs 13(1):70-79. doi: 10.1177/1099800410378733
97. Katsuura S, Kamezaki Y, Yamagishi N, Kuwano Y, Nishida K, Masuda K, Tanahashi T, Kawai T, Arisawa K, Rokutan K (2011) Circulating vascular endothelial growth factor is independently and negatively associated with trait anxiety and depressive mood in healthy Japanese university students. Int J Psychophysiol 81(1):38-43. doi: 10.1016/j.ijpsycho.2011.04.004
98. Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H (2010) Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm 117(9):1119-1122. doi: 10.1007/s00702-010-0452-1
99. Elfving B, Plougmann PH, Wegener G (2010) Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett 474(1):13-16. doi: 10.1016/j.neulet.2010.02.063
100. Miskowiak K, O'Sullivan U, Harmer CJ (2007) Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry 62(11):1244-1250
101. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ (2008) Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 33(3):611-618
102. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM (2003) Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28(1):148-152
103. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006) Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59(9):816-820
104. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, Harmer CJ (2010) Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology 210(3):419-428
105. Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ (2005) Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 21(5):1304-1314
106. Howell KR, Kutiyanawalla A, Pillai A (2011) Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS ONE 6(5):e20198. doi: 10.1371/journal.pone.0020198
107. Bergstrom A, Jayatissa MN, Mork A, Wiborg O (2008) Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res 1196:41-52. doi: 10.1016/j.brainres.2007.12.025
108. Palmer TD, Willhoite AR, Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425(4):479-494
109. Fournier NM, Duman RS (2011) Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res. doi: 10.1016/j.bbr.2011.04.022
110. Warner-Schmidt JL, Duman RS (2007) VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104(11):4647-4652
111. Lee JS, Jang DJ, Lee N, Ko HG, Kim H, Kim YS, Kim B, Son J, Kim SH, Chung H, Lee MY, Kim WR, Sun W, Zhuo M, Abel T, Kaang BK, Son H (2009) Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J Neurosci 29(26):8493-8505. doi: 10.1523/JNEUROSCI.1321-09.2009
112. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS (2009) Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34(11):2459-2468. doi: 10.1038/npp.2009.68
113. Kiuchi T, Lee H, Mikami T (2012) Regular exercise cures depression-like behavior via VEGF-Flk-1 signaling in chronically stressed mice. Neuroscience 207:208-217. doi: 10.1016/j.neuroscience.2012.01.023
114. Ibrahim L, Duncan W, Luckenbaugh DA, Yuan P, Machado-Vieira R, Zarate CA Jr (2011) Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull 86(1-2):129-133. doi: 10.1016/j.brainresbull.2011.06.003
115. Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setala-Soikkeli E, Mononen N, Lehtimaki T, Leinonen E (2010) Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett 477(3):105-108. doi: 10.1016/j.neulet.2010.04.039
116. Udo H, Yoshida Y, Kino T, Ohnuki K, Mizunoya W, Mukuda T, Sugiyama H (2008) Enhanced adult neurogenesis and angiogenesis and altered affective behaviors in mice overexpressing vascular endothelial growth factor 120. J Neurosci 28(53):14522-14536
117. Lucki I (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8(6-7):523-532
118. Segi-Nishida E, Warner-Schmidt JL, Duman RS (2008) Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci USA 105(32):11352-11357. doi: 10.1073/pnas.0710858105
119. Oh DH, Kim BW, Choi M, Lee G, Choi JS, Hyeon S (2012) Changes in vascular endothelial growth factor (VEGF) induced by the Morris water maze task. Mol Cells 33(3):295-300. doi: 10.1007/s10059-012-2254-9
120. Pati S, Orsi SA, Moore AN, Dash PK (2009) Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory. Brain Res 1256:85-91. doi: 10.1016/j.brainres.2008.11.086
121. Kim BW, Choi M, Kim YS, Park H, Lee HR, Yun CO, Kim EJ, Choi JS, Kim S, Rhim H, Kaang BK, Son H (2008) Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal 20(4):714-725. doi: 10.1016/j.cellsig.2007.12.009
122. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, During MJ (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36(8):827-835
123. Plaschke K, Staub J, Ernst E, Marti HH (2008) VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 214(2):285-292. doi: 10.1016/j.expneurol.2008.08.014
124. Licht T, Goshen I, Avital A, Kreisel T, Zubedat S, Eavri R, Segal M, Yirmiya R, Keshet E (2011) Reversible modulations of neuronal plasticity by VEGF. Proc Natl Acad Sci USA. doi: 10.1073/pnas.1007640108
125. Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29(7):1321-1330
126. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681):239-242
127. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Muller M, Hassouna I, Hannke K, Sperling S, Radyushkin K, El-Kordi A, Schulze L, Ronnenberg A, Wolf F, Brose N, Rhee JS, Zhang W, Ehrenreich H (2008) Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6:37
128. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105(31):10925-10930
129. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(19):10526-10531
130. Conley AJ, Mohib K, Jevnikar AM, Brandle JE (2009) Plant recombinant erythropoietin attenuates inflammatory kidney cell injury. Plant Biotechnol J 7(2):183-199
131. Wang YJ, Liu YD, Chen J, Hao SJ, Hu T, Ma GH, Su ZG (2010) Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int J Pharm 386(1-2):156-164
132. Johnson DL, Middleton SA, McMahon F, Barbone FP, Kroon D, Tsao E, Lee WH, Mulcahy LS, Jolliffe LK (1996) Refolding, purification, and characterization of human erythropoietin binding protein produced in Escherichia coli. Protein Expr Purif 7(1):104-113
133. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. Science 273(5274):464-471
134. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395(6701):511-516
135. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35(5):1681-1691
136. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274):458-464
137. Pankratova S, Kiryushko D, Sonn K, Soroka V, Kohler LB, Rathje M, Gu B, Gotfryd K, Clausen O, Zharkovsky A, Bock E, Berezin V (2010) Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 133(Pt 8):2281-2294. doi: 10.1093/brain/awq101
138. Pankratova S, Gu B, Kiryushko D, Korshunova I, Kohler LB, Rathje M, Bock E, Berezin V (2012) A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival. J Neurochem 121(6):915-923
139. Constantinescu SN, Ghaffari S, Lodish HF (1999) The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 10(1):18-23
140. Mahmood A, Lu D, Qu C, Goussev A, Zhang ZG, Lu C, Chopp M (2007) Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 107(2):392-397
141. Chong ZZ, Kang JQ, Maiese K (2002) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22(5):503-514
142. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, Madri JA, Ment LR (2002) Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 277(13):11410-11415. doi: 10.1074/jbc.M111085200
143. Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19(14):5731-5740
144. Zacchigna S, Lambrechts D, Carmeliet P (2008) Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 9(3):169-181
145. Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA (2006) Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev Biol 289(2):329-335. doi: 10.1016/j.ydbio.2005.10.016